Motley Fool: Is iShares Nasdaq Biotechnology Index Fund a Buy?

Biotechnology stocks get a lot of attention. It’s easy to be enamored with the curing of disease, and the financial results that could follow the successful introduction of a new treatment can be game-changing. But, alas, it isn’t as simple…

Advertisements

Motley Fool: 3 Stocks That Could Double Your Money

Doubling your money isn’t as difficult as it might seem. You just need the right stocks and enough time. I’m not talking about 50 years. There are plenty of stocks with the potential to at least double in five years…

Motley Fool: 5 Things You Need to Know From Vertex Pharmaceuticals’ Q1 Earnings Update

Quarterly updates just look too easy for Vertex Pharmaceuticals (NASDAQ:VRTX). The biotech announced its first-quarter earnings results on Tuesday. Yet again, Vertex posted strong revenue and earnings growth that blew past Wall Street analysts’ estimates. Vertex’s management team fielded questions…

Motley Fool: 5 Top Pharmaceutical Stocks to Buy in 2019

More than $320 billion was spent on prescription drugs in the U.S. in 2016, a figure that’s expected to nearly double to $610 billion by 2021, according to IQVIA (formerly QuintilesIMS). With so much money being spent on necessary medicines,…